Search results

21 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Advances in melanoma treatment focus of UNC conference
At the 10th Annual UNC Conference on Melanoma and Complex Skin Cancers: A Multidisciplinary Perspective, experts in melanoma treatment presented advances in treating the disease on Thursday. The conference, held at the William and Ida Friday Center for Continuing Education, drew dermatologists, surgeons, medical oncologists and other health care providers to hear presentations on topics ranging from immunotherapy drugs and targeted treatments for metastatic disease, radiation strategies, and chemotherapy to prevent skin cancer.
Located in News
Nanoparticle form of bone loss prevention drug effective against cancer, preclinical study finds
A preclinical study led by a UNC Lineberger researcher found that a nanoparticule form of a drug used to prevent bone loss was effective against small-cell lung and prostate cancer cells. The results were published in the journal Biomaterials.
Located in News
UNC experts talk ‘Cancer Moonshot’ with Vice President Biden
As part of the “Cancer Moonshot” federal initiative to spur breakthroughs in cancer research, Biden hosted a roundtable discussion on Wednesday at the Duke University School of Medicine that featured cancer experts and leaders from UNC. Among the experts chosen for the panel were Stephanie Wheeler, PhD, UNC Lineberger member and assistant professor of health policy and management at the UNC Gillings School of Global Public Health and Niklaus Steiner, UNC-Chapel Hill professor and co-founder of the Chapel Hill-based Be Loud! Sophie Foundation, which supports adolescents and young adults with cancer.
Located in News
UNC Startup Receives Federal Grant to Kick-Start Cancer Research Commercialization
G-Zero Therapeutics funded under Qualifying Therapeutic Discovery Project
Located in News / 2011 News
Study finds need for improved end-of-life care for parents with terminal cancer
Based on a survey of widowed fathers who had lost a spouse to cancer, UNC Lineberger researchers reported in the journal BMJ Palliative Care that additional research and improved end-of-life care are needed to specifically help dying parents as well as their families.
Located in News
Device hits pancreatic tumors hard with toxic four-drug cocktail, sparing the body
A new implantable device delivers first-line treatment for pancreatic cancer directly to tumors, bypassing bloodstream and limiting widespread side effects. A team of researchers from the University of North Carolina including Drs. Jen Jen Yeh and Joseph DeSimone, has shown in preclinical research that the device can deliver a particularly toxic dose of drugs directly to pancreatic tumors to stunt their growth or, in some cases, shrink them. This approach would also spare the patient toxic side effects.
Located in News
UNC researchers make groundbreaking discovery, use skin cells to kill cancer
A preclinical study led by a UNC Lineberger Comprehensive Cancer Center researcher found that skin cells turned cancer-killing stem cells hunt down and destroy the deadly remnants inevitably left behind when a brain tumor is surgically removed.
Located in News
Preclinical study finds no benefit for diabetes drug in pancreatic cancer
UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.
Located in News
UNC Lineberger researchers uncover promising direction for the treatment of pancreatic cancers driven by KRAS mutation
In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.
Located in News
Online e-cigarette searches number in the millions, but few focus on vaping health risk or quitting smoking
A study published recently in the American Journal of Preventive Medicine found that Google searches about electronic cigarettes were more commonly related to shopping for e-cigarettes, while quitting smoking represented less than 1 percent of e-cigarette searches in each of 2013 and in 2014. The study’s senior author was Rebecca S. Williams, MHS, PhD, a UNC Lineberger member.
Located in News